🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

518 results for “Cho” Clear

  1. A study of niraparib in combination with abemaciclib for late line treatment of ovarian cancer: a single center, open label, single arm, phase Ib/II trial (NICHOL TRIAL)

    Fondazione Telethon ETS

    Ovarian cancer

    phase 2 other active

    1 trial

  2. ABC294640

    RedHill Biopharma

    Cholangiocarcinoma

    phase 2 small molecule completed

    1 trial

  3. ACETYLCYSTEINE , DEXAMETHASONE , DIPHENHYDRAMINE , GLUCOSE

    Inhibrx Biosciences

    Unresectable or metastatic conventional chondrosarcoma

    phase 2 small molecule active

    1 trial

  4. AG-120

    Agios Netherlands B.V.

    Chondrosarcoma

    phase 2 small molecule active

    1 trial

  5. AG-120/S95031 250mg film-coated tablet, IMFINZI 50 mg/mL concentrate for solution for infusion., Gemcitabin Hikma 38 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    The George Institute

    Locally advanced, unresectable or metastatic cholangiocarcinoma with an IDH1 mutation

    phase 2 small molecule active

    1 trial

  6. AGN 211745

    Allergan Pharmaceuticals International Limited

    Choroid Neovascularization

    phase 2 small molecule terminated

    1 trial

  7. AKCEA-ANGPTL3-LRX

    IONIS PHARMACEUTICALS INC

    Homozygous Familial Hypercholesterolemia

    phase 2 small molecule terminated

    1 trial

  8. APD334

    Arena Pharmaceutical Enterprises Limited

    Primary Biliary Cholangitis

    phase 2 small molecule terminated

    1 trial

  9. ARO-ANG 3 Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Homozygous Familial Hypercholesterolemia

    phase 2 small molecule terminated

    1 trial

  10. AZD0780, AZD0780, AZD0780 Placebo, AZD0780

    AstraZeneca AB

    Dyslipidemia Dyslipidemias are alterations to the plasma lipid profile associated often with clinical condition. A common form of dyslipidemia is Hypercholesterolemia due to high level of LDL-cholesterol, which is a major risk factor for Cardiovascular Disease (CVD), such as Ischemic Heart Disease and Ischemic Stroke. CVD is a leading cause of global mortality and a contributor to disability.

    phase 2 small molecule active

    1 trial

  11. Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.

    BioMarin Pharmaceutical Australia Pty Ltd

    Achondroplasia

    phase 2 small molecule active

    1 trial

  12. An open-label, single-arm extension study to evaluate the long-term safety, tolerability, and efficacy of KL1333 (napazimone) in patients with primary mitochondrial disease

    Pharming Technologies B.V.

    Adult patients with primary mitochondrial disease

    phase 2 other active

    1 trial

  13. Anti-human CCL24 monoclonal antibody (CM-101)

    Chemomab Therapeutics

    Primary Sclerosing Cholangitis

    phase 2 mab active

    1 trial

  14. Apatinib

    The First People's Hospital of Lianyungang

    Intrahepatic Cholangiocarcinoma

    phase 2 small molecule active

    1 trial

  15. Aramchol

    Galmed Pharmaceuticals

    Non-Alcoholic Fatty Liver Disease

    phase 2 small molecule completed

    1 trial

  16. Aramchol

    Galmed Pharmaceuticals

    Fatty Liver

    phase 2 small molecule completed

    1 trial

  17. Aramchol

    Galmed Pharmaceuticals

    Gallstones

    phase 2 small molecule terminated

    1 trial

  18. Aramchol meglumine

    Galmed Pharmaceuticals

    Primary Sclerosing Cholangitis

    phase 2 small molecule terminated

    1 trial

  19. Atorvastatin Oral Tablet

    Chongqing Precision Biotech Co., Ltd

    Mild Cognitive Impairment

    phase 2 small molecule active

    1 trial

  20. Atorvastatin injection

    CUMBERLAND PHARMACEUTICALS INC

    Hypercholesterolemia

    phase 2 small molecule completed

    1 trial

  21. BCMA CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Multiple Myeloma

    phase 2 mab active

    2 trials

  22. BCMA targeted prime CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Multiple Myeloma

    phase 2 mab active

    1 trial

  23. BGJ398 (infigratinib)

    BridgeBio Oncology Therapeutics

    Advanced Cholangiocarcinoma

    phase 2 small molecule terminated

    1 trial

  24. BI 685509, Placebo matching BI 685509 PRD9566383, Placebo matching BI 685509 PRD9566375, BI 685509, BI 685509, Placebo matching BI 685509 PRD9566374

    Boehringer Ingelheim

    clinically significant portal hypertension (CSPH) in decompensated cirrhosis due to non-cholestatic liver disease

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources